Results 231 to 240 of about 19,810 (255)

Overview and Current Status of Peptide Receptor Radionuclide Therapy

Surgical Oncology Clinics of North America, 2020
Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment of patients with metastatic neuroendocrine tumors, delivering modest objective tumor response rates but notable survival and symptomatic benefits. The first PRRT approved by the US Food and Drug Administration was lutetium 177-DOTATATE and is for use in adults with ...
David L, Bushnell, Kellie L, Bodeker
openaire   +2 more sources

Peptide Receptor Radionuclide Therapy (PRRT)

2016
There has been tremendous progress over recent years on the development of peptide receptor radionuclide therapy (PRRT) for the treatment of a variety of cancers. In this technology, peptides radiolabeled with therapeutic radionuclides are targeted to cell-surface receptors which are often overexpressed on the membrane surface of tumor cells.
Ashutosh Dash
exaly   +2 more sources

Peptide Receptor Radionuclide Therapy: Preclinical Findings

2016
Somatostatin is a cyclopeptide that has a broad inhibitory effect on the secretion of hormones such as growth hormone, glucagon, and insulin. The molecular basis of the use of radiolabeled octreotide in scintigraphy and radionuclide therapy is receptor-mediated internalization and cellular retention of the radionuclide.
Capello, A (Astrid), Breeman, Wout, Bernard, HF, Jong, Marion, Krenning, Eric   +4 more
openaire   +2 more sources

Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy

Seminars in Nuclear Medicine, 2010
In the 1980s, the (111)In-labeled somatostatin analog OctreoScan (Covidien, Hazelwood, MO) was developed for imaging of somatostatin receptor subtype 2 (sst(2)) overexpressing tumors. On the basis of this success, peptide receptor radionuclide therapy (PRRT) was developed using similar somatostatin analogs with different therapeutic radionuclides ...
Pool, Stefan, Krenning, Eric, Koning, Gerben, van Eijck, Casper, Teunissen, Jaap, Kam, BLR, Valkema, R., Kwekkeboom, Dik, Jong, Marion   +8 more
openaire   +3 more sources

Peptide receptor radionuclide therapy in malignant insulinoma

Endocrine-Related Cancer
The management of malignant insulinoma (MI) presents dual management challenges of hypoglycaemia and tumour control. This study aims to analyse long-term outcomes of PRRT for the treatment of MI. We retrospectively reviewed consecutive patients with MI treated with [177Lu]Lu-DOTATATE (LuTATE) at two Australian NET centres between 2004 and 2022.
David A Pattison, Grace Kong, Timothy Akhurst, Matthew Burge, Cherie Chiang, Michael S Hofman, Te-Jui Hung, Amanda Love, Michael Michael, Satomi Okano, Aravind S Ravi Kumar, Nirupa Sachithanandan, David Wyld, Rodney J Hicks   +13 more
openaire   +3 more sources

Peptide Receptor Radionuclide Therapy for Sarcoidosis [PDF]

American Journal of Respiratory and Critical Care Medicine, 2016
Lapa, Constantin, Grigoleit, Götz Ulrich, Hänscheid, Heribert, Klinker, Erdwine, Jung, Pius, Herrmann, Ken, Schirbel, Andreas, Böck, Markus, Buck, Andreas K., Pelzer, Theo   +9 more
openaire   +2 more sources

Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours

Current Radiopharmaceuticals, 2019
Background: The incidence of pancreatic Neuroendocrine Tumours (pNETs) has increased considerably in the last few decades. The characteristic features of this tumour and the development of new investigative and therapeutic methods had a great impact on its management.
Shahad, Alsadik, Siraj, Yusuf, Adil, Al-Nahhas   +2 more
openaire   +2 more sources

Dosimetry for Peptide Receptor Radionuclide Therapy

2012
For over more than a decade, the progressive evolution of Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of tumors expressing somatostatin receptors has been constantly challenging—and challenged by—dosimetry. The improvements reached in the therapeutical applications of 90Y- and 177Lu- radiolabeled peptides are considerable, and new ...
Marta Cremonesi, Christiane Schuchardt
openaire   +1 more source

Peptide receptor radionuclide therapy in neuroendocrine neoplasms and related tumors: from fundamentals to personalization and the newer experimental approaches

Expert Review of Precision Medicine and Drug Development, 2023
Sandip Basu Dnb
exaly  

Peptide receptor radionuclide therapy

2010
[No abstract available]
openaire   +1 more source